Aldeyra Therapeutics
ALDX
76 hedge funds and large institutions have $101M invested in Aldeyra Therapeutics in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 16 closing their positions.
198% more call options, than puts
Call options by funds: $761K | Put options by funds: $255K
94% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 16
1.72% more ownership
Funds ownership: 59.71% → 61.44% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
4% less funds holding
Funds holding: 79 → 76 (-3)
31% less capital invested
Capital invested by funds: $148M → $101M (-$46.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$2.45M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.45M |
| 3 |
BlackRock
New York
|
+$1.48M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.28M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$863K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.48M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.27M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$1.24M |
| 4 |
Millennium Management
New York
|
-$1.1M |
| 5 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
-$948K |
ALDX Hedge Fund Activity: Q2 2019 in Review
76 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2019, worth a combined $101M — down 31% from $148M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ALDX and 15 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 31 added.
The largest buyer was 683 Capital Management, adding an estimated $2.45M. The largest seller was Verition Fund Management, exiting entirely with an estimated $2.48M sold.
- 76 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2019, down from 79 in Q1 2019.
- Funds reported $101M of Aldeyra Therapeutics stock for Q2 2019, down 31% quarter-over-quarter.
- 15 funds opened new Aldeyra Therapeutics positions in Q2 2019 and 16 closed out, a net change of -1 holder.
- The largest Aldeyra Therapeutics buyer in Q2 2019 was 683 Capital Management, an estimated $2.45M added.
- The largest Aldeyra Therapeutics seller in Q2 2019 was Verition Fund Management, an estimated $2.48M sold.
Based on aggregated 13F filings for Q2 2019.